Neal J. Meropol

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 2.3K citations

Medicine, Oncology, Pharmacotherapy +15

Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

Steven J. Cohen, Cornelis J.A. Punt, Nicholas Iannotti et al. · Journal of Clinical Oncology · 2008 · 1.8K citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +16

Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

Fairooz F. Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2002 · 1.7K citations

Medicine, Oncology, Pharmacotherapy +13

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer et al. · Journal of Clinical Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text

Medicine, Genetics, Oncology +17